Cubist Flexes Sales Force Built On Cubicin To Market AstraZeneca Anti-infective
This article was originally published in The Pink Sheet Daily
Executive Summary
Company shores up its hospital products as it evolves into an acute-care focused business.
You may also be interested in...
Optimer Looks To Partner C. Diff Candidate After Trial Success
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.
Optimer Looks To Partner C. Diff Candidate After Trial Success
OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.
Sales Growth Leaves Analysts Bullish On Cubist’s Cubicin
Injectable antibiotic continues to pry away market share from generic vancomycin.